1.53
price down icon1.29%   -0.02
after-market Dopo l'orario di chiusura: 1.53
loading
Precedente Chiudi:
$1.55
Aprire:
$1.57
Volume 24 ore:
213.28K
Relative Volume:
0.44
Capitalizzazione di mercato:
$47.95M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.3825
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
+5.52%
1M Prestazione:
+9.29%
6M Prestazione:
-71.88%
1 anno Prestazione:
-81.32%
Intervallo 1D:
Value
$1.51
$1.58
Intervallo di 1 settimana:
Value
$1.40
$1.68
Portata 52W:
Value
$0.87
$9.2899

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Nome
Outlook Therapeutics Inc
Name
Telefono
(609) 619-3990
Name
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Name
Dipendente
23
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-14
Name
Ultimi documenti SEC
Name
OTLK's Discussions on Twitter

Confronta OTLK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.53 47.95M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-02 Downgrade Chardan Capital Markets Buy → Neutral
2024-03-27 Aggiornamento BTIG Research Neutral → Buy
2024-02-15 Aggiornamento Chardan Capital Markets Neutral → Buy
2024-01-25 Aggiornamento Guggenheim Neutral → Buy
2023-12-27 Aggiornamento CapitalOne Equal Weight → Overweight
2023-08-31 Downgrade Chardan Capital Markets Buy → Neutral
2023-08-31 Downgrade H.C. Wainwright Buy → Neutral
2023-08-30 Downgrade BTIG Research Buy → Neutral
2023-08-30 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-08-30 Downgrade CapitalOne Overweight → Equal Weight
2023-08-30 Downgrade Guggenheim Buy → Neutral
2023-07-13 Iniziato CapitalOne Overweight
2023-04-03 Iniziato Guggenheim Buy
2023-02-06 Iniziato Cantor Fitzgerald Overweight
2022-10-31 Iniziato BTIG Research Buy
2022-09-13 Iniziato Chardan Capital Markets Buy
2019-09-11 Iniziato Ladenburg Thalmann Buy
2019-05-16 Iniziato Oppenheimer Outperform
2019-04-22 Iniziato Ascendiant Capital Markets Buy
Mostra tutto

Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie

pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 19, 2025

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN

Apr 19, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail

Apr 17, 2025
pulisher
Apr 12, 2025

25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Outlook Therapeutics Approves Retention Incentive for CFO - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com

Apr 10, 2025
pulisher
Apr 10, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 09, 2025

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025
pulisher
Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025

Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):